![Mark DiPaolo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark DiPaolo
Keine laufenden Positionen mehr
Vermögen: 3 Mio $ am 31.05.2026
Profil
Mark A. DiPaolo is currently Chairman at Syndeio Biosciences and Independent Director at OneIM Acquisition Corp.
Former roles include Chairman at Innoviva, Inc. from 2023 to 2026, Independent Director at Novelion Therapeutics, Inc. from 2017 to 2018, Independent Director at Amarin Corp.
Plc from 2023 to 2025, Senior Managing Director at Sarissa Capital Acquisition Corp.
from 2020 to 2023, Attorney at Willkie Farr & Gallagher LLP from 2017 to 2018, and Member at Icahn Capital LP from 2005 to 2013.
Education includes undergraduate studies at Fordham University and graduate studies at Georgetown University Law Center.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INNOVIVA, INC. 0,19 % | 04.05.2026 | 140.492 ( 0,19 % ) | 3 Mio $ | 31.05.2026 |
-.--% | 14.01.2026 | 25.000 ( -.--% ) | 250 000 $ | 31.05.2026 |
| 18.04.2025 | 8.020 ( 0 % ) | 116 210 $ | 31.05.2026 |
Aktive Positionen von Mark DiPaolo
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Mark DiPaolo
| Unternehmen | Position | Ende |
|---|---|---|
| INNOVIVA, INC. | Vorsitzender | 12.05.2026 |
| AMARIN CORPORATION PLC | Direktor/Vorstandsmitglied | 13.05.2025 |
| SARISSA CAPITAL ACQUISITION CORP. | Corporate Officer/Principal | 13.04.2023 |
| NOVELION THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 13.09.2018 |
Willkie Farr & Gallagher LLP
 Willkie Farr & Gallagher LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01.09.2018 |
Ausbildung von Mark DiPaolo
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
38
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amarin Corp. Plc
 Amarin Corp. Plc Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops and commercializes therapeutics to improve cardiovascular health | Health Technology |
Icahn Capital LP
 Icahn Capital LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Willkie Farr & Gallagher LLP
Willkie Farr & Gallagher LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Innoviva, Inc.
 Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
Fordham University
 Fordham University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University Law Center
 Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Sarissa Capital Acquisition Corp.
 Sarissa Capital Acquisition Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
Wählen Sie MarketScreener 
